| MANNKIND CORP. NEW DL-,01 |
| USA |
| Gesundheit |
| US56400P7069 / A2DMZL |
| NNFN (Frankfurt) / MNKD (NASDAQ) |
| FRA:NNFN, ETR:NNFN, NNFN:GR, NASDAQ:MNKD |
| - |
| https://mannkindcorp.com/ |
|
MannKind Corporation is a biopharmaceutical company focused on developing and commercializing innovative inhaled therapies and devices for patients with cardiometabolic and orphan lung diseases, including diabetes, pulmonary hypertension, and fluid o..
>Volltext.. |
| 1042.7 Mio. EUR |
| 1305.48 Mio. EUR |
| 317.09 Mio. EUR |
| 37.36 Mio. EUR |
| -21.02 Mio. EUR |
| -0.07 EUR |
| 383.79 Mio. EUR |
| 46.44 Mio. EUR |
| 16.86 Mio. EUR |
| 0.99 |
| 13.52% |
| -174.35% |
| - |
| - |
| - |
| MANNKIND |
| 24.07.26 |